Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE Combined With Sorafenib and PD-1 mAb in the Treatment of BCLC B/C Hepatocellular Carcinoma: Single Arm, Single Center, Open Label Study

NCT04518852 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.

NCT NCT04518852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04518852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE Combined With Sorafenib and PD-1 mAb in the Treatment of BCLC B/C Hepatocellular Carcinoma: Single Arm, Single Center, Open Label Study
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2020
Completion date
January 31, 2023
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, digestive system neoplasms, hepatocellular carcinoma, liver diseases, liver neoplasms, molecular mechanisms of pharmacological action, protein kinase inhibitors, sorafenib